Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Gross Margin (2021 - 2025)

Historic Gross Margin for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Q3 2025 value amounting to 89.28%.

  • Rhythm Pharmaceuticals' Gross Margin rose 7900.0% to 89.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 89.4%, marking a year-over-year increase of 7900.0%. This contributed to the annual value of 89.73% for FY2024, which is 17400.0% up from last year.
  • Rhythm Pharmaceuticals' Gross Margin amounted to 89.28% in Q3 2025, which was up 7900.0% from 88.57% recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Gross Margin peaked at 95.83% during Q2 2022, and registered a low of 50.0% during Q2 2021.
  • Its 5-year average for Gross Margin is 86.22%, with a median of 88.49% in 2024.
  • Its Gross Margin has fluctuated over the past 5 years, first surged by 458300bps in 2022, then crashed by -74600bps in 2023.
  • Quarter analysis of 5 years shows Rhythm Pharmaceuticals' Gross Margin stood at 87.01% in 2021, then rose by 1bps to 88.3% in 2022, then fell by -2bps to 86.66% in 2023, then increased by 5bps to 90.95% in 2024, then decreased by -2bps to 89.28% in 2025.
  • Its last three reported values are 89.28% in Q3 2025, 88.57% for Q2 2025, and 88.85% during Q1 2025.